scholarly journals Granulocyte Colony-Stimulating Factor-Producing Bladder Cancer

2019 ◽  
Vol 12 (2) ◽  
pp. 603-607 ◽  
Author(s):  
Ryota Morinaga ◽  
Takashi Kawahara ◽  
Shinnosuke Kuroda ◽  
Yoshiaki Inayama ◽  
Hiroji Uemura
Keyword(s):  
Bladder Cancer ◽  
Blood Cell ◽  
Cell Count ◽  
Bladder Tumor ◽  
Resected Specimen ◽  
Granulocyte Colony Stimulating Factor ◽  
Colony Stimulating Factor ◽  
Blood Cell Count ◽  
Gross Hematuria ◽  
Stimulating Factor

Granulocyte colony-stimulating factor (G-CSF)-producing bladder cancer is rare, with only 75 cases reported in Japan. A 67-year-old woman was referred to our institution for the further examination of gross hematuria. Cystoscopy revealed a 7-cm bladder tumor. The initial white blood cell count was 17,100/μL, and a transurethral resected specimen showed G-CSF expression. CT revealed that the tumor had invaded the colon. As the patient had uncontrollable schizophrenia, radical cystectomy was abandoned. We herein report a case of G-CSF-producing bladder tumor.

Growth and reproductive traits of F1-generation transgenic goats for human granulocyte-colony stimulating factor

2018 ◽  
Vol 58 (7) ◽  
pp. 1218
Author(s):  
R. I. T. P. Batista ◽  
J. M. G. Souza-Fabjan ◽  
D. Í. A. Teixeira ◽  
L. M. Melo ◽  
V. J. F. Freitas
Keyword(s):  
Blood Cell ◽  
Cell Count ◽  
White Blood Cell Count ◽  
White Blood Cell ◽  
Reproductive Parameters ◽  
Granulocyte Colony Stimulating Factor ◽  
Colony Stimulating Factor ◽  
Blood Cell Count ◽  
Transgenic Lines ◽  
Stimulating Factor

To ensure that animal welfare requirements and phenotypic characteristics of the newly produced transgenic lines are not compromised, an evaluation of all individuals is necessary. This can be inferred by the analysis of the growth and reproduction parameters. The present study was designed to determine the impact of the insertion of human granulocyte-colony stimulating factor (hG-CSF) transgene on growth and reproductive characteristics in first-generation (F1) goats from two transgenic lines. Bodyweight (BW) development (BW at birth, mean BW gain before weaning, BW at weaning, mean BW gain after weaning, BW at puberty), as well as reproductive parameters (age at puberty, ejaculate volume, concentration, total sperm per ejaculate, massal motility, progressive individual motility, major and minor defects) were similar (P > 0.05) between transgenic (T) and non-transgenic (NT) goats. Significant (P < 0.05) differences in mean (±s.d.) white blood cell count were observed between T and NT in first day of life (174.6 ± 14.7 × 103 and 15.0 ± 4.0 × 103 cells/µL), and during (66.8 ± 21.1 × 103 and 17.0 ± 4.6 × 103 cells/µL) and after (36.6 ± 4.0 × 103 and 15.5 ± 2.2 × 103 cells/µL) suckling, even though hG-CSF has not been detected in blood serum in any analysis. Although other cell counts were occasionally higher in T animals, differential counts showed that this difference was mainly due to an increased number of neutrophils, which represents 84.6%, 67.2% and 56.8% of total white blood cell count respectively, in the three time periods. Kidney and liver biochemical analyses indicated that all goats were healthy. Thus, it is possible to assume that all animals are normal and had no deleterious effects on either growth or reproductive parameters by the presence of transgene or as a consequence of leukocyte profile alteration.

The incidence and timing of leukocyte overshoot after pegfilgrastim administration

2018 ◽  
Vol 25 (4) ◽  
pp. 869-874 ◽  
Author(s):  
Eiseki Usami ◽  
Michio Kimura ◽  
Mina Iwai ◽  
Makiko Go ◽  
Hiroki Asano ◽  
...  
Keyword(s):  
Blood Cell ◽  
Cell Count ◽  
White Blood Cell Count ◽  
White Blood Cell ◽  
Reference Value ◽  
Granulocyte Colony Stimulating Factor ◽  
Colony Stimulating Factor ◽  
Blood Cell Count ◽  
Cell Counts ◽  
Stimulating Factor

Introduction Pegfilgrastim is a PEGylated formulation of filgrastim with a long half-life. It is highly convenient and less burdensome for patients. However, white blood cell count may temporarily increase after administration; in particular, a leukocyte overshoot may be observed. The present study retrospectively examined the incidence and timing of leukocyte overshoot after pegfilgrastim administration. Patients and methods Fifty-five patients (118 occasions of pegfilgrastim) were evaluated. Leukocyte overshoot was defined as white blood cell count ≥10,000/mm3 exceeding the reference value. Results Leukocyte overshoot was observed in 71.2% (84/118) occasions, in 76.4% (42/55) patients. The maximum white blood cell count ≥30,000/mm3 was observed in 30.5% (36/118) occasions in 45.5% (25/55) patients and was observed in 39.3% (33/84) occasions on day 1 after pegfilgrastim administration and 26.2% (22/84) on day 2. Leukocyte overshoot has been observed in only 23.1% (9/39) patients administered with normal granulocyte colony-stimulating factor. However, there were no patients with white blood cell counts ≥30,000/mm3. Conclusion There was a higher frequency of occurrence of leukocyte overshoot in response to pegfilgrastim than in response to normal granulocyte colony-stimulating factor. High incidence of leukocyte overshoot was observed when blood was collected 1–2 days after administration of pegfilgrastim. It is important for patients to understand the characteristics of pegfilgrastim by conducting pharmaceutical guidance.

scholarly journals Ritodrine-Induced Agranulocytosis: A Case Report and Literature Review

2020 ◽  
Vol 2020 ◽  
pp. 1-3
Author(s):  
Atsushi Daimon ◽  
Misa Nunode ◽  
Takumi Sano ◽  
Tomohito Tanaka ◽  
Daisuke Fujita ◽  
...  
Keyword(s):  
Blood Cell ◽  
White Blood Cell ◽  
Preterm Labor ◽  
Continuous Intravenous Infusion ◽  
Granulocyte Colony Stimulating Factor ◽  
Colony Stimulating Factor ◽  
Premature Labor ◽  
Blood Cell Count ◽  
Ritodrine Hydrochloride ◽  
Stimulating Factor

Ritodrine hydrochloride is used for preterm labor, although serious side effects, including agranulocytosis, are reported. We report a case of ritodrine hydrochloride-induced agranulocytosis accompanied by bacteremia due to catheter infection. At 24 weeks of gestation, a female patient presented due to threatened premature labor and was administered continuous intravenous infusion of ritodrine hydrochloride. On day 36 after starting intravenous ritodrine hydrochloride, she was diagnosed with agranulocytosis. The white blood cell and granulocyte count nadirs were 1,660/μl and 438/μl. The cumulative dose of ritodrine hydrochloride was 2,610 mg. Ritodrine therapy was immediately stopped, and she was given an intravenous injection of antibiotics and granulocyte colony-stimulating factor. From her blood culture, methicillin-sensitive Staphylococcus aureus was detected. However, she started vaginal delivery two days after we stopped the ritodrine infusion. When using ritodrine hydrochloride, it is necessary to frequently check the white blood cell count, regardless of the total dose and treatment period.

Pembrolizumab Treatment and Pathologic Therapeutic Evaluation for Granulocyte Colony-stimulating Factor-producing Bladder Cancer

2020 ◽  
Vol 43 (4) ◽  
pp. 134-138
Author(s):  
Yuka Muramatsu-Maekawa ◽  
Tomoki Taniguchi ◽  
Hiroki Ito ◽  
Keita Nakane ◽  
Taku Kato ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Granulocyte Colony Stimulating Factor ◽  
Colony Stimulating Factor ◽  
Therapeutic Evaluation ◽  
Stimulating Factor

Stimulatory effects of granulocyte colony-stimulating factor on colony- forming units-spleen (CFU-S) differentiation and pre-CFU-S proliferation in mice

Blood ◽  
1991 ◽  
Vol 77 (12) ◽  
pp. 2597-2602 ◽  
Author(s):  
T Tanaka ◽  
T Suda ◽  
J Suda ◽  
T Inoue ◽  
Y Hirabayashi ◽  
...  
Keyword(s):  
Mouse Bone Marrow ◽  
Granulocyte Colony Stimulating Factor ◽  
Colony Stimulating Factor ◽  
Blood Cell Count ◽  
Colony Forming Units ◽  
Immature Myeloid Cells ◽  
Polymerase Chain ◽  
Buffer Control ◽  
Macrophage Colony ◽  
Stimulating Factor

Abstract Granulocyte colony-stimulating factor (G-CSF) was reported to increase the number of colony-forming units-spleen (CFU-S) and multilineage colonies as well as myeloid-committed cells. We investigated the effects of G-CSF on myeloid progenitors and primitive stem cells in a mouse bone marrow transplantation (BMT) system. Lethally irradiated mice received BM cells from untreated or 5-fluorouracil-treated mice, and then were administered G-CSF or carrier buffer (control) for 5 days from immediately after BMT. A pre-CFU-S assay was performed by the repeated transplantation of BM cells from the first BMT recipients to other mice. By the method of polymerase chain reaction, most of the spleen colonies in the secondary recipients were confirmed to be derived from the first donors. G-CSF did not increase the peripheral white blood cell count significantly, but did increase the number of immature myeloid cells and granulocyte-macrophage colony-forming cells in the BM. The number of erythroid cells in the BM was initially suppressed and then increased by G-CSF treatment. In addition, the pre- CFU-S assay showed an increase in pre-CFU-S cells due to G-CSF administration. The number of spleen colonies of first BMT recipients did not increase, but a higher percentage of them were committed to a certain lineage by G-CSF treatment. These findings suggest that G-CSF has important roles in the early stages of hematopoiesis.

Sign in / Sign up

Export Citation Format

Share Document